Sort
48,018 grants matching “immunotherapy”
Targeting dual functions of PD-L1 for cancer therapy
$363,713Haidong Dong · Mayo Clinic Rochester · R01 · FY2021 · CA
Mechanisms coupling DEK to oncogenesis
$363,713Lisa M. Privette Vinnedge · Cincinnati Childrens Hosp Med Ctr · R37 · FY2022 · CA
PD-L1 Intracellular RNA binding function regulates immune suppression
$363,713Robert W Mutter · Mayo Clinic Rochester · R01 · FY2025 · CA
Monocyte promotion of therapy resistance by immune and non-immune mechanisms
$363,713Yi Lin · Mayo Clinic Rochester · R01 · FY2020 · CA
PD-L1 Intracellular RNA binding function regulates immune suppression
$363,713Robert W Mutter · Mayo Clinic Rochester · R01 · FY2022 · CA
Mechanisms coupling DEK to oncogenesis
$363,713Lisa M. Privette Vinnedge · Cincinnati Childrens Hosp Med Ctr · R37 · FY2021 · CA
Monocyte promotion of therapy resistance by immune and non-immune mechanisms
$363,713Yi Lin · Mayo Clinic Rochester · R01 · FY2018 · CA
PD-L1 Intracellular RNA binding function regulates immune suppression
$363,713Robert W Mutter · Mayo Clinic Rochester · R01 · FY2021 · CA
Targeting dual functions of PD-L1 for cancer therapy
$363,713Haidong Dong · Mayo Clinic Rochester · R01 · FY2025 · CA
Monocyte promotion of therapy resistance by immune and non-immune mechanisms
$363,713Yi Lin · Mayo Clinic Rochester · R01 · FY2016 · CA
Development of B-cell-based vaccine for Glioblastoma
$363,713Catalina Lee Chang · Northwestern University At Chicago · R37 · FY2021 · CA
Mechanisms coupling DEK to oncogenesis
$363,713Lisa M. Privette Vinnedge · Cincinnati Childrens Hosp Med Ctr · R37 · FY2020 · CA
Monocyte promotion of therapy resistance by immune and non-immune mechanisms
$363,713Yi Lin · Mayo Clinic Rochester · R01 · FY2017 · CA
In Vivo Prevention of Murine GVHD
$363,687Bruce R. Blazar · University Of Minnesota · R01 · FY2008 · AI
Mechanistic investigations of microbiome-driven aryl hydrocarbon receptor activity and macrophage function in pancreatic cancer.
$363,672Tracy L McGaha · University Health Network · R01 · FY2023 · CA
Training In Cell and Gene Therapy
$363,647Helen E Heslop · Baylor College Of Medicine · T32 · FY2019 · HL
In Vivo Prevention of Murine GVHD
$363,598Bruce R. Blazar · University Of Minnesota · R01 · FY2009 · AI
Lipids and Myeloid Cell Function in Cancer
$363,568Dmitry Isaac Gabrilovich · Wistar Institute · R01 · FY2016 · CA
IMMUNE ACTIVATION OF NK AND TUMOR SPECIFIC T CELLS BY IN
$363,496Mount Sinai School Of Medicine Of Nyu · R01 · FY2002 · CA
Microneedles for allergy immunotherapy
$363,495Harvinder Singh Gill · Texas Tech University · R01 · FY2020 · AI
Optimizing Response to Immune Checkpoint Inhibitor Therapy for Breast Cancer: A Role for Inhibitors of the PI3K pathway
$363,453Ann Richmond · Vanderbilt University · R01 · FY2021 · CA
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE
$363,450Lieping Chen · Johns Hopkins University · R01 · FY2007 · CA
Expanding the Therapeutic Window of Nanoparticle STING Agonists for Cancer Immunotherapy
$363,450John Tanner Wilson · Vanderbilt University · R01 · FY2020 · CA
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE
$363,450Lieping Chen · Johns Hopkins University · R01 · FY2010 · CA
MOLECULAR MECHANISMS OF TUMOR-INDUCED TOLERANCE
$363,450Lieping Chen · Johns Hopkins University · R01 · FY2008 · CA